uniQure N.V. QURE

uniQure (NasdaqGS:QURE) is back in focus after new 36- and 48-month data for its Huntington’s gene therapy, AMT-130, sparked sharp swings in the share price and renewed debate about the program. uniQure’s share price has been hit hard in the wake of the mixed AMT-130 update, with a 7-day share price return down 36.95% and a 30-day move down 49.52%, even though the year-to-date share price return is still up 3.29% and the 3-year total shareholder return is very large at roughly 2.6x. This...

uniQure lost more than a third of its value in a single session after Huntington's data spooked investors, but Wall Street's price target still points to triple-digit upside. Whether that gap represents opportunity or denial depends on one number that cuts both ways.